Your browser doesn't support javascript.
loading
Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway.
Hannan, Katherine M; Soo, Priscilla; Wong, Mei S; Lee, Justine K; Hein, Nadine; Poh, Perlita; Wysoke, Kira D; Williams, Tobias D; Montellese, Christian; Smith, Lorey K; Al-Obaidi, Sheren J; Núñez-Villacís, Lorena; Pavy, Megan; He, Jin-Shu; Parsons, Kate M; Loring, Karagh E; Morrison, Tess; Diesch, Jeannine; Burgio, Gaetan; Ferreira, Rita; Feng, Zhi-Ping; Gould, Cathryn M; Madhamshettiwar, Piyush B; Flygare, Johan; Gonda, Thomas J; Simpson, Kaylene J; Kutay, Ulrike; Pearson, Richard B; Engel, Christoph; Watkins, Nicholas J; Hannan, Ross D; George, Amee J.
Afiliação
  • Hannan KM; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Bioche
  • Soo P; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Wong MS; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum
  • Lee JK; Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Hein N; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Poh P; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Wysoke KD; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Williams TD; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Montellese C; Department of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland.
  • Smith LK; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Al-Obaidi SJ; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Núñez-Villacís L; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Pavy M; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • He JS; ANU Centre for Therapeutic Discovery, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Parsons KM; ANU Centre for Therapeutic Discovery, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Loring KE; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Morrison T; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Diesch J; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Burgio G; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Ferreira R; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Feng ZP; The John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia.
  • Gould CM; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Madhamshettiwar PB; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Flygare J; Lund Stem Cell Center, Lund University, BMC A12, Lund, Sweden.
  • Gonda TJ; School of Pharmacy, University of Queensland, Brisbane, QLD 4102, Australia.
  • Simpson KJ; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Kutay U; Department of Biology, Institute of Biochemistry, ETH Zurich, Zurich, Switzerland.
  • Pearson RB; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Bioche
  • Engel C; Regensburg Center for Biochemistry, University of Regensburg, 93053 Regensburg, Germany.
  • Watkins NJ; Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle-Upon-Tyne, UK.
  • Hannan RD; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Bioche
  • George AJ; ACRF Department of Cancer Biology and Therapeutics and Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Acton, ACT 2601, Australia; ANU Centre for Therapeutic Discovery, John Curtin School of Medical Research, Australian National Univers
Cell Rep ; 41(5): 111571, 2022 11 01.
Article em En | MEDLINE | ID: mdl-36323262
ABSTRACT
The nucleolar surveillance pathway monitors nucleolar integrity and responds to nucleolar stress by mediating binding of ribosomal proteins to MDM2, resulting in p53 accumulation. Inappropriate pathway activation is implicated in the pathogenesis of ribosomopathies, while drugs selectively activating the pathway are in trials for cancer. Despite this, the molecular mechanism(s) regulating this process are poorly understood. Using genome-wide loss-of-function screens, we demonstrate the ribosome biogenesis axis as the most potent class of genes whose disruption stabilizes p53. Mechanistically, we identify genes critical for regulation of this pathway, including HEATR3. By selectively disabling the nucleolar surveillance pathway, we demonstrate that it is essential for the ability of all nuclear-acting stresses, including DNA damage, to induce p53 accumulation. Our data support a paradigm whereby the nucleolar surveillance pathway is the central integrator of stresses that regulate nuclear p53 abundance, ensuring that ribosome biogenesis is hardwired to cellular proliferative capacity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-mdm2 Tipo de estudo: Screening_studies Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-mdm2 Tipo de estudo: Screening_studies Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article